Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Abstract Background Neoadjuvant programmed death receptor-1 (PD-1) inhibitors have drawn increasing attention in locally advanced head and neck squamous cell carcinoma (HNSCC). In this study, we investigated the safety and efficacy of gemcitabine and cisplatin (GP), combined with a PD-1 inhibitor, i...

Full description

Bibliographic Details
Main Authors: Xiaotao Huang, Qiaodan Liu, Guihua Zhong, Yingpeng Peng, Ye Liu, Lizhong Liang, Haiyu Hong, Weineng Feng, Shuang Yang, Yaqin Zhang, Shiping Xian, Zhanyu Li, Yuling Zhou, Zhaoyuan Zhang, Wen Jiang, Jun Liang, Zhi-gang Liu
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Head and neck squamous cell carcinoma
Immunotherapy
Neoadjuvant treatment
Pathological response rate
Online Access:https://doi.org/10.1186/s13046-022-02510-2

Internet

https://doi.org/10.1186/s13046-022-02510-2

Similar Items